NMDA receptor antagonists

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, NMDA receptor antagonists, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Nutraceutical, Psychedelic drug

The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Key Points: 
  • The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.
  • Todays announcements are further evidence of the synergies between our growing clinic network and our contract research offerings, said Ketamine Ones Interim CEO, Adam Deffett.
  • We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One, added Mr. Deffett.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Retrieved on: 
Tuesday, July 27, 2021
Psychoactive drugs, Entheogens, Branches of biology, NMDA receptor antagonists, Indole alkaloids, Drug rehabilitation, Ibogaine, Tabernanthe iboga, Legal status of ibogaine by country

During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.

Key Points: 
  • During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.
  • As first announced on July 13, 2021, MINDCURE has also filed patent applications for two routes of chemical synthesis of ibogaine.
  • Ibogaine is a psychoactive substance that can be found naturally in the roots of the iboga tree, which grows in Africa.
  • "We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Sedatives, Ketamine, Neurocognition, IRPS

IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.

Key Points: 
  • IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.
  • NeuroCatch is expected to remain a key part of IRPs service offering as Ketamine One expands its network to new veteran-centric markets across Canada.
  • Unique service offerings such as NeuroCatch help Ketamine Ones clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time.
  • Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy.

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Retrieved on: 
Tuesday, July 20, 2021
Branches of biology, Psychoactive drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Neurotransmitters, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.

Key Points: 
  • Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.
  • Arbormentis LLC is a privately-held drug discovery company engaged in potentially transformative innovations for CNS diseases.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

Retrieved on: 
Tuesday, July 13, 2021
Psychoactive drugs, Branches of biology, Entheogens, Drugs, NMDA receptor antagonists, Indole alkaloids, Ibogaine, Tryptamines, Tabernanthe iboga, Psychedelic drug, Psychedelic therapy, Organic chemistry

The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.

Key Points: 
  • The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.
  • The identified routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds.
  • The two chemical synthesis routes are currently being assessed to determine which one will be selected for further development first.
  • "Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy.

Global Anesthetics Market Report 2020-2030: Bupivacaine; Ropivacaine; Lidocaine; Chloroprocaine; Articaine; Benzocaine; Propofol; Sevoflurane; Desflurane; Dexmedetomidine; Remifentanil; Midazolam - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, Infectious diseases, Surgery, Other Health, General Health, Pharmaceutical, Drugs, Psychoactive drugs, Medical specialties, Anesthesia, General anesthetics, NMDA receptor antagonists, Anesthetic, Local anesthetic, Ketamine, General anaesthetic

The "Anesthetics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anesthetics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
  • The anesthetics market consists of sales of drugs that cause a relaxing sensation to calm patients during surgery and remove the sensation of pain.
  • The anesthetics market is divided into general anesthetics, regional anesthetics and local anesthetics.
  • Stringent guidelines and regulations imposed by regulatory bodies are one of the important restraints for the anesthetics market.

Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer

Retrieved on: 
Tuesday, June 15, 2021
Psychoactive drugs, Drugs, Neurochemistry, Entheogens, NMDA receptor antagonists, Nicotinic antagonists, Ibogaine, Tryptamines, Tabernanthe iboga, Ketamine

Ketamine treatments on anxiety, depression and PTSD using brain mapping technology, stated Ben Kaplan, CEO of Ehave.

Key Points: 
  • Ketamine treatments on anxiety, depression and PTSD using brain mapping technology, stated Ben Kaplan, CEO of Ehave.
  • Dr. Jeffrey Kamlet, M.D, FASAM, DABAM is recognized as the worlds expert on cardiac safety in ibogaine treatment.
  • Dr. Kamlet served as the Global Ibogaine Therapy Alliance's Chief Medical Advisor, as well as Editor in Chief on the Global Ibogaine Therapy Alliance's Clinical Guidelines for Ibogaine-Assisted Detoxification.
  • Additionally, he has worked as an Associate Director and Medical Director for several emergency departments in Southern Florida as well EMS Medical Director for the City of Pembroke Park, FL.

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre

Retrieved on: 
Wednesday, June 9, 2021
Psychoactive drugs, Drugs, NMDA receptor antagonists, General anesthetics, Antidepressants, Nicotinic antagonists, Sedatives, Esketamine, Ketamine

The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.

Key Points: 
  • The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.
  • Both Esketamine and intravenous (IV) Ketamine are the first glutamate-based treatments demonstrated to be rapidly effective in adults suffering from TRD.
  • "We have been encouraged to see increased availability and access to esketamine and ketamine for adults experiencing TRD.
  • We have been equally interested to assure that implementation of these rapid-acting treatments is conducted according to the best of science and clinical practice parameters," said Dr. Roger S. McIntyre, CEO, Braxia Scientific.

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Glutamate, Biology, NMDA receptor antagonists, Molecular neuroscience, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid

An archived replay of the event will be available for one year after the conclusion of the presentation.

Key Points: 
  • An archived replay of the event will be available for one year after the conclusion of the presentation.
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Retrieved on: 
Thursday, June 3, 2021
Psychoactive drugs, Drugs, Neurochemistry, NMDA receptor antagonists, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, General anesthetics, Ketamine, Clinic

Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.

Key Points: 
  • Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.
  • The IRP team is excited to join Ketamine One and combine resources to grow its clinics across Canada.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.